A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

NCT07465029 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

1300

Enrollment

INDUSTRY

Sponsor class

Conditions

Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Interventions

DRUG: Erythropoiesis-stimulating agents (ESAs)
BIOLOGICAL: Luspatercept
DRUG: Lenalidomide
DRUG: Hypomethylating agents (HMAs)
BIOLOGICAL: Reb blood cell transfusion

Sponsor

Bristol-Myers Squibb